Bromhexine hydrochloride for prophylaxis against COVID-19

INTERVENTION: Intervention 1: Intervention group: Receiving Bromhexine 8 mg 3 times a day for 14 days in patients with history of close contact to confirmed COVID‐19 in past 4 days. Intervention 2: Control group: Receiving placebo 3 times a day for 14 days in patients with history of close contact to confirmed COVID‐19 in past 4 days. CONDITION: Condition 1: COVID‐19. Condition 2: COVID‐19. ; COVID‐19, virus identified ; COVID‐19, virus not identified U07.1 U07.2 PRIMARY OUTCOME: Incidence of COVID‐19 disease. Timepoint: At day 14. Method of measurement: Clinical assessment. Ordinal Scale of COVID‐19 disease severity. Timepoint: Censored at Day 14. Method of measurement: Clinical assessment. SECONDARY OUTCOME: Confirmed COVID‐19 diagnosis. Timepoint: Day 14. Method of measurement: Self report. Hospitalization or death. Timepoint: Day 14. Method of measurement: Phone call. Sign and Symptoms compatible with COVID‐19. Timepoint: day 14. Method of measurement: Self report. Treatment withdrawal or discontinuation. Timepoint: day 14. Method of measurement: self report. INCLUSION CRITERIA: Exposure and close contact (defined as being within 6 feet for a period of 15 minutes or more in a 24 hour period or 5 minutes or more for healthcare associated exposure) to a COVID‐19 case within 4 days before entering the study must agree not to enroll in another investigational study prior to completion of Day 14 of study Individuals who have the ability to understand and desire to sign the informed consent Age of 18 years or more